Congress Park Capital LLC Grows Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Congress Park Capital LLC raised its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 24.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,455,495 shares of the biotechnology company's stock after purchasing an additional 477,417 shares during the period. Heron Therapeutics comprises 1.4% of Congress Park Capital LLC's holdings, making the stock its 23rd largest position. Congress Park Capital LLC owned about 1.61% of Heron Therapeutics worth $3,757,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HRTX. Cutter & CO Brokerage Inc. acquired a new position in shares of Heron Therapeutics during the 3rd quarter worth about $39,000. Y Intercept Hong Kong Ltd purchased a new stake in Heron Therapeutics during the 3rd quarter worth approximately $39,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Heron Therapeutics during the second quarter valued at approximately $41,000. Sei Investments Co. purchased a new position in Heron Therapeutics in the 2nd quarter valued at $44,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Heron Therapeutics during the 3rd quarter worth $45,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on HRTX shares. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Stock Up 3.8 %

Shares of HRTX traded up $0.06 during midday trading on Friday, reaching $1.63. The company had a trading volume of 1,513,118 shares, compared to its average volume of 1,459,256. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93. The firm has a 50 day simple moving average of $1.47 and a 200-day simple moving average of $1.97. The stock has a market cap of $247.92 million, a PE ratio of -9.06 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to analyst estimates of $36.40 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. As a group, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.